Key Drivers
- Persistent Losses
- Weak Liquidity
- Negative Equity
AIAI Summary
RARE is now a commercial-execution and liquidity bet: upside depends on Crysvita durability and a fast FAYUVI launch, while persistent cash burn, $1.2B debt, and weak liquidity make dilution or refinancing increasingly likely without near-term cash-flow improvement.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Persistent Losses
- •Weak Liquidity
- •Negative Equity
RARE's improving margins are outweighed by persistent losses, accelerating cash burn, heavy debt, and negative equity, warranting caution despite solid revenue growth.
Price Behavior
Key Price Behavior Insights:
- •Sharp monthly decline
- •Gap-down repricing
- •Support rebound
RARE fell sharply over the last month, with $12.88 support and $14.88–$15.30 resistance, while the September gap-down warrants data-adjustment verification.
Abrupt drop from $26.53 to $14.85 on 2026-09-03 may reflect a corporate action or data discontinuity
Sentiment & News
Key News Insights:
- •Angelman Trial Failure
- •New Drug Approvals
- •Investor Investigations
Ultragenyx faces a volatile outlook as Angelman trial failure and legal scrutiny offset landmark rare-disease approvals and renewed investor optimism.
Near-term sentiment remains volatile, with regulatory wins supporting long-term value but clinical and legal risks weighing on shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings